Reading across the published trial designs, the recently expanded dose-finding work, and the regulatory signals from both the FDA and the EMA, the breeds most likely to see the largest real-world lifespan extension in the first wave of approved canine longevity drugs are mid-sized companion breeds — Labradors, Golden Retrievers, Border Collies, Australian Shepherds, and similar dogs in the 20-35 kilogram range.

The reasoning runs in three steps. First, almost every pivotal study has been weighted toward this size range, which means the dose data is more reliable here than at the extremes. Second, the safety data is also better here, because adverse event rates in the trial cohorts have been consistent enough across mid-sized breeds that regulators are likely to be comfortable approving a single dose protocol covering this group, where the giant and toy breed extremes will probably need separate approvals or off-label adjustment. Third, the underlying biology of mid-sized aging — neither the rapid, inflammation-driven decline of giant breeds nor the slower, dental-and-cardiac progression typical of toys — fits the most-studied geroscience mechanisms most cleanly.

Giant-breed owners should not read this as bad news. The same compounds will eventually be studied at the giant end of the size range, and several university programmes are already preparing the dose-finding work that would support a giant-specific label expansion. The realistic timeline is twelve to eighteen months behind the mid-sized launch, not years.

Toy-breed owners face a different timeline issue. Toy breeds tend to have longer baseline lifespans, which means the absolute size of any longevity gain is smaller in proportional terms and may take longer to demonstrate in studies. The first toy-specific data is unlikely to surface until at least the second post-launch year, and the case for early enrollment in trials is correspondingly weaker.

For owners trying to decide whether their breed is in the first wave, the most practical signal is whether your breed is named in any of the currently published trial registries. We maintain a breed-by-breed list on the breeds section, updated whenever a new trial registry is published or amended.